SPORE Core B. Pathology and Tissue Resources Core. The Tissue Resources and Molecular Pathology Core will provide routine and innovative tissues and materials, as well as conventional and molecular pathology assistance, essential for achieving the aims of the SPORE projects. Routine materials include tumors and non-malignant lung specimens and tumor cell lines. Over 2,500 well-characterized tumors with annotated clinical data and 200 cell lines have been banked, and over 15,000 aliquots of tumor or cell line pellets, RNA or DNA or paraffin sections are available to SPORE investigators. State-of-art molecular pathology facilities devoted to lung cancer translational research directed by experienced lung cancer molecular pathologists are available.
Our Aim 1 is to collect, process, store, catalog and distribute tissues, cells and blood specimens, both malignant and non-malignant, and relevant clinico-pathologic data, as requested by the various component projects of the SPORE program.
Aim 2 is to develop and utilize innovative or routine tissue and cell resources that will aid in the successful completion of the SPORE program aims. Innovative materials include: a) cell pellets and tissue microarrays (TMAs) and high throughput image analysis of in situ techniques, b) new lung cancer cell lines and lung cancer xenografts made directly from patient specimens, c) new immortalized and non-immortalized human bronchial epithelial cells (HBECs) and 3-dimensional organotypic cultures.
Aim 3 is to perform and interpret tissue-based molecular methodologies in close collaboration with the component projects of the SPORE program to satisfy their approved aims. This includes immunohistochemistry (IHC) information on over 90 lung cancer relevant biomarkers on the TMAs with information stored in an image database and integrated with the clinical annotations.
Aim 4 is to promote collaboration among investigators in this SPORE, other lung cancer SPORES, other investigators in MD Anderson Cancer Center, UT Southwestern Medical Center, and other investigators nationally and internationally pursuing lung cancer relevant research. All of our five projects in this application will utilize CORE materials. Heavy utilization of our routine and innovative materials, and close interactions with the SPORE investigators will greatly aid the successful completion of the aims of our SPORE proposal. The SPORE Tissue Resource Core is designed and has operated as a facility receiving support from several other sources beyond SPORE funding including in a manner non-overlapping with other Cancer Center activities at both MD Anderson and UT Southwestern Medical Centers. This means that SPORE discoveries and data have far reaching beneficial effects across the range of lung cancer research conducted at these two institutions.
|Tu, Huakang; Heymach, John V; Wen, Chi-Pang et al. (2016) Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S. Sci Rep 6:26760|
|Jafri, Mohammad A; Ansari, Shakeel A; Alqahtani, Mohammed H et al. (2016) Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med 8:69|
|Tong, Pan; Diao, Lixia; Shen, Li et al. (2016) Selecting Reliable mRNA Expression Measurements Across Platforms Improves Downstream Analysis. Cancer Inform 15:81-9|
|Hao, Chuncheng; Shao, Ruping; Raju, Uma et al. (2016) Accumulation of RNA-dependent protein kinase (PKR) in the nuclei of lung cancer cells mediates radiation resistance. Oncotarget 7:38235-38242|
|Guijarro-MuÃ±oz, Irene; Roarty, Emily B; Heymach, John V (2016) Bevacizumab beyond disease progression for advanced non-small cell lung cancer: Does persistence have its rewards? Cancer 122:1047-9|
|Schabath, M B; Welsh, E A; Fulp, W J et al. (2016) Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene 35:3209-16|
|Kundu, S T; Byers, L A; Peng, D H et al. (2016) The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. Oncogene 35:173-86|
|Mak, Milena P; Tong, Pan; Diao, Lixia et al. (2016) A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res 22:609-20|
|Bendris, Nawal; Stearns, Carrie J S; Reis, Carlos R et al. (2016) Sorting nexin 9 negatively regulates invadopodia formation and function in cancer cells. J Cell Sci 129:2804-16|
|Hensley, Christopher T; Faubert, Brandon; Yuan, Qing et al. (2016) Metabolic Heterogeneity in Human Lung Tumors. Cell 164:681-94|
Showing the most recent 10 out of 908 publications